BSE Live
Mar 16, 16:01Prev. Close
370.10
Open Price
369.40
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 16, 15:59Prev. Close
368.75
Open Price
370.00
Bid Price (Qty.)
366.15 (100)
Offer Price (Qty.)
0.00 (0)
| Key Financial Ratios of SMS Pharmaceuticals (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 3.86 | 4.90 | 4.78 | 4.21 | 4.92 | |
| Diluted EPS (Rs.) | 3.86 | 4.90 | 4.78 | 4.21 | 4.92 | |
| Cash EPS (Rs.) | 6.47 | 7.17 | 7.13 | 6.47 | 7.21 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 43.40 | 40.16 | 35.57 | 31.02 | 34.77 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 43.40 | 40.16 | 35.57 | 31.02 | 34.77 | |
| Dividend / Share(Rs.) | 0.25 | 0.25 | 0.25 | 0.20 | 0.20 | |
| Revenue from Operations/Share (Rs.) | 48.66 | 54.92 | 54.66 | 51.76 | 71.26 | |
| PBDIT/Share (Rs.) | 10.05 | 11.05 | 11.31 | 9.01 | 10.96 | |
| PBIT/Share (Rs.) | 7.44 | 8.77 | 8.96 | 6.74 | 8.67 | |
| PBT/Share (Rs.) | 6.00 | 7.37 | 7.13 | 4.91 | 6.65 | |
| Net Profit/Share (Rs.) | 3.86 | 4.90 | 4.78 | 4.21 | 4.92 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 20.64 | 20.11 | 20.69 | 17.40 | 15.38 | |
| PBIT Margin (%) | 15.28 | 15.96 | 16.38 | 13.02 | 12.16 | |
| PBT Margin (%) | 12.32 | 13.41 | 13.04 | 9.49 | 9.32 | |
| Net Profit Margin (%) | 7.93 | 8.91 | 8.74 | 8.12 | 6.90 | |
| Return on Networth / Equity (%) | 8.89 | 12.19 | 13.43 | 13.56 | 14.14 | |
| Return on Capital Employed (%) | 13.06 | 17.22 | 19.06 | 16.11 | 9.13 | |
| Return on Assets (%) | 5.21 | 7.18 | 7.79 | 7.10 | 6.34 | |
| Total Debt/Equity (X) | 0.35 | 0.38 | 0.43 | 0.51 | 0.63 | |
| Asset Turnover Ratio (%) | 65.69 | 80.59 | 89.12 | 87.44 | 91.90 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 1.51 | 1.42 | 1.39 | 1.07 | 1.24 | |
| Quick Ratio (X) | 0.62 | 0.49 | 0.50 | 0.44 | 0.67 | |
| Inventory Turnover Ratio (X) | 3.19 | 3.41 | 4.30 | 4.74 | 5.35 | |
| Dividend Payout Ratio (NP) (%) | 15.61 | 6.15 | 5.03 | 5.72 | 4.06 | |
| Dividend Payout Ratio (CP) (%) | 9.31 | 4.20 | 3.37 | 3.71 | 2.77 | |
| Earnings Retention Ratio (%) | 84.39 | 93.85 | 94.97 | 94.28 | 95.94 | |
| Cash Earnings Retention Ratio (%) | 90.69 | 95.80 | 96.63 | 96.29 | 97.23 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 345.32 | 641.85 | 740.55 | 847.07 | 876.89 | |
| EV/Net Operating Revenue (X) | 0.84 | 1.38 | 1.60 | 1.93 | 1.45 | |
| EV/EBITDA (X) | 4.06 | 6.86 | 7.74 | 11.11 | 9.45 | |
| MarketCap/Net Operating Revenue (X) | 0.55 | 1.13 | 1.35 | 1.66 | 1.17 | |
| Retention Ratios (%) | 84.38 | 93.84 | 94.96 | 94.27 | 95.93 | |
| Price/BV (X) | 0.61 | 1.55 | 2.07 | 2.76 | 2.40 | |
| Price/Net Operating Revenue | 0.55 | 1.13 | 1.35 | 1.66 | 1.17 | |
| Earnings Yield | 0.14 | 0.08 | 0.06 | 0.05 | 0.06 |
18.02.2026
SMS Pharma Consolidated December 2025 Net Sales at Rs 210.45 crore, up 21.4% Y-o-Y
10.02.2026
SMS Pharma Standalone December 2025 Net Sales at Rs 210.45 crore, up 21.4% Y-o-Y
09.02.2026
05.01.2026
18.02.2026
SMS Pharma Consolidated December 2025 Net Sales at Rs 210.45 crore, up 21.4% Y-o-Y
10.02.2026
SMS Pharma Standalone December 2025 Net Sales at Rs 210.45 crore, up 21.4% Y-o-Y
14.11.2025
SMS Pharma Consolidated September 2025 Net Sales at Rs 242.43 crore, up 23.22% Y-o-Y
12.11.2025
SMS Pharma Standalone September 2025 Net Sales at Rs 242.43 crore, up 23.22% Y-o-Y
16.03.2026
15.03.2026
13.03.2026
13.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth